Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Trial ID or NCT#
NCT04088890
Status
NOT RECRUITING
Purpose
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Official Title
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Matthew Frank
Blood and marrow transplant specialist,
Hematologist-Oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Crystal Mackall
Contact us to find out if this trial is right for you.
Contact
Juliana Craig
650-736-0912
View on ClinicalTrials.gov
